Potential Specific Therapies in COVID-19

Overview

Journal Ther Adv Respir Dis

Publisher Sage Publications

Specialties Pharmacology
Pulmonary Medicine

Date 2020 May 22

PMID 32436445

Citations 11

Authors

Muhammad Hamdan Gul

Zin Mar Htun

Nauman Shaukat

Muhammad Imran

Ahmad Khan

Affiliations

Soon will be listed here.

Abstract

COVID-19 has grown into a global pandemic that has strained healthcare throughout the world. There is a sense of urgency in finding a cure for this deadly virus. In this study, we reviewed the empiric options used in common practice for COVID-19, based on the literature available online, with an emphasis on human experiences with these treatments on severe acute respiratory syndrome-associated coronavirus (SARS-COV-1) and other viruses. Convalescent blood products are the most promising potential treatment for use in COVID-19. The use of chloroquine or hydroxychloroquine (HCQ), remdesivir, and tocilizumab are some of the other promising potential therapies; however, they are yet to be tested in randomized clinical trials (RCTs). The use of lopinavir-ritonavir did not prove beneficial in a large RCT. The use of corticosteroids should be avoided in COVID-19 pneumonia unless used for other indications, based on the suggestion of harm in patients with SARS-COV-1 and Middle Eastern Respiratory Syndrome (MERS) infection.

Citing Articles

COVID-19: An Overview of SARS-CoV-2 Variants-The Current Vaccines and Drug Development.

Bostanghadiri N, Ziaeefar P, Mofrad M, Yousefzadeh P, Hashemi A, Darban-Sarokhalil D Biomed Res Int. 2023; 2023:1879554.

PMID: 37674935 PMC: 10480030. DOI: 10.1155/2023/1879554.

The role of the endothelium in severe acute respiratory syndrome coronavirus 2 infection and pathogenesis.

Passi R, Brittan M, Baker A Curr Opin Physiol. 2023; 34:100670.

PMID: 37159613 PMC: 10066588. DOI: 10.1016/j.cophys.2023.100670.

Correlation between COVID-19 and hepatitis B: A systematic review.

He Y, Jiang Z, Wu N, Bian N, Ren J World J Gastroenterol. 2022; 28(46):6599-6618.

PMID: 36569273 PMC: 9782843. DOI: 10.3748/wjg.v28.i46.6599.

Emergent Drug and Nutrition Interactions in COVID-19: A Comprehensive Narrative Review.

Agagunduz D, Celik M, Citar Daziroglu M, Capasso R Nutrients. 2021; 13(5).

PMID: 34064534 PMC: 8147951. DOI: 10.3390/nu13051550.

COVID-19 combined with liver injury: Current challenges and management.

Deng M, Chen Y, Yang M, Liu Y, Chen H, Tang X World J Clin Cases. 2021; 9(15):3487-3497.

PMID: 34046449 PMC: 8130088. DOI: 10.12998/wjcc.v9.i15.3487.

References

Chen J, Liu D, Liu L, Liu P, Xu Q, Xia L . [A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19]. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020; 49(2):215-219. PMC: 8800713. DOI: 10.3785/j.issn.1008-9292.2020.03.03. View

Poynard T, Marcellin P, Lee S, Niederau C, Minuk G, Ideo G . Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group.... Lancet. 1998; 352(9138):1426-32. DOI: 10.1016/s0140-6736(98)07124-4. View

Savarino A, Shytaj I . Chloroquine and beyond: exploring anti-rheumatic drugs to reduce immune hyperactivation in HIV/AIDS. Retrovirology. 2015; 12:51. PMC: 4472405. DOI: 10.1186/s12977-015-0178-0. View

van Griensven J, Edwards T, Baize S . Efficacy of Convalescent Plasma in Relation to Dose of Ebola Virus Antibodies. N Engl J Med. 2016; 375(23):2307-2309. PMC: 5833944. DOI: 10.1056/NEJMc1609116. View

Walmsley S, Bernstein B, King M, Arribas J, Beall G, Ruane P . Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med. 2002; 346(26):2039-46. DOI: 10.1056/NEJMoa012354. View

Delang L, Abdelnabi R, Neyts J . Favipiravir as a potential countermeasure against neglected and emerging RNA viruses. Antiviral Res. 2018; 153:85-94. DOI: 10.1016/j.antiviral.2018.03.003. View

Loutfy M, Blatt L, Siminovitch K, Ward S, Wolff B, Lho H . Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. JAMA. 2003; 290(24):3222-8. DOI: 10.1001/jama.290.24.3222. View

. [Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia]. Zhonghua Jie He He Hu Xi Za Zhi. 2020; 43(3):185-188. DOI: 10.3760/cma.j.issn.1001-0939.2020.03.009. View

Lee N, Chan K, Hui D, Ng E, Wu A, Chiu R . Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. J Clin Virol. 2004; 31(4):304-9. PMC: 7108318. DOI: 10.1016/j.jcv.2004.07.006. View

10.

Gaeta G, Precone D, Felaco F, Bruno R, Spadaro A, Stornaiuolo G . Premature discontinuation of interferon plus ribavirin for adverse effects: a multicentre survey in 'real world' patients with chronic hepatitis C. Aliment Pharmacol Ther. 2002; 16(9):1633-9. DOI: 10.1046/j.1365-2036.2002.01331.x. View

11.

Joshi S, Butala N, Patwardhan M, Daver N, Kelkar D . Low cost anti-retroviral options: chloroquine based ARV regimen combined with hydroxyurea and lamivudine: a new economical triple therapy. J Assoc Physicians India. 2005; 52:597-8. View

12.

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G . A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020; 382(19):1787-1799. PMC: 7121492. DOI: 10.1056/NEJMoa2001282. View

13.

Taccone F, Gorham J, Vincent J . Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base. Lancet Respir Med. 2020; 8(6):539-541. PMC: 7159849. DOI: 10.1016/S2213-2600(20)30172-7. View

14.

Al-Tawfiq J, Hinedi K, Ghandour J, Khairalla H, Musleh S, Ujayli A . Middle East respiratory syndrome coronavirus: a case-control study of hospitalized patients. Clin Infect Dis. 2014; 59(2):160-5. PMC: 7108071. DOI: 10.1093/cid/ciu226. View

15.

Bodenheimer Jr H, Lindsay K, Davis G, Lewis J, Thung S, Seeff L . Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology. 1997; 26(2):473-7. DOI: 10.1002/hep.510260231. View

16.

Shibata M, Aoki H, Tsurumi T, Sugiura Y, Nishiyama Y, Suzuki S . Mechanism of uncoating of influenza B virus in MDCK cells: action of chloroquine. J Gen Virol. 1983; 64(Pt 5):1149-56. DOI: 10.1099/0022-1317-64-5-1149. View

17.

Hung I, To K, Lee C, Lee K, Chan K, Yan W . Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis. 2011; 52(4):447-56. PMC: 7531589. DOI: 10.1093/cid/ciq106. View

18.

Channappanavar R, Fehr A, Vijay R, Mack M, Zhao J, Meyerholz D . Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice. Cell Host Microbe. 2016; 19(2):181-93. PMC: 4752723. DOI: 10.1016/j.chom.2016.01.007. View

19.

Cheng Y, Wong R, Soo Y, Wong W, Lee C, Ng M . Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2004; 24(1):44-6. PMC: 7088355. DOI: 10.1007/s10096-004-1271-9. View

20.

Sung J, Wu A, Joynt G, Yuen K, Lee N, Chan P . Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak. Thorax. 2004; 59(5):414-20. PMC: 1746995. DOI: 10.1136/thx.2003.014076. View